Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrology | 6 | 2022 | 144 | 2.120 |
Why?
|
| Renal Dialysis | 9 | 2022 | 842 | 1.750 |
Why?
|
| Peritoneal Dialysis | 5 | 2022 | 118 | 1.640 |
Why?
|
| Kidney Failure, Chronic | 6 | 2020 | 864 | 1.510 |
Why?
|
| Critical Illness | 8 | 2021 | 591 | 1.480 |
Why?
|
| Renal Replacement Therapy | 4 | 2021 | 141 | 1.200 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2024 | 715 | 1.160 |
Why?
|
| Acute Kidney Injury | 3 | 2021 | 614 | 0.780 |
Why?
|
| Intensive Care Units | 8 | 2021 | 483 | 0.730 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 100 | 0.670 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 38 | 0.670 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 606 | 0.660 |
Why?
|
| Uromodulin | 1 | 2019 | 15 | 0.650 |
Why?
|
| Pyelonephritis | 1 | 2019 | 26 | 0.640 |
Why?
|
| Health Policy | 2 | 2020 | 213 | 0.640 |
Why?
|
| Specialization | 1 | 2019 | 76 | 0.640 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 214 | 0.620 |
Why?
|
| Anticoagulants | 2 | 2021 | 581 | 0.550 |
Why?
|
| Ambulatory Care | 1 | 2020 | 378 | 0.540 |
Why?
|
| Hospital Mortality | 8 | 2021 | 1010 | 0.470 |
Why?
|
| Respiratory Insufficiency | 2 | 2021 | 231 | 0.460 |
Why?
|
| Caregivers | 4 | 2024 | 571 | 0.430 |
Why?
|
| Physicians | 1 | 2019 | 583 | 0.420 |
Why?
|
| Prone Position | 2 | 2021 | 32 | 0.420 |
Why?
|
| Delphi Technique | 5 | 2024 | 202 | 0.410 |
Why?
|
| Patient Positioning | 2 | 2021 | 54 | 0.400 |
Why?
|
| United States | 14 | 2021 | 10651 | 0.400 |
Why?
|
| Kidney Diseases | 2 | 2021 | 478 | 0.390 |
Why?
|
| Pandemics | 4 | 2021 | 1099 | 0.370 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 455 | 0.340 |
Why?
|
| Hypoxia | 1 | 2021 | 248 | 0.330 |
Why?
|
| Renal Insufficiency | 2 | 2022 | 234 | 0.320 |
Why?
|
| Humans | 32 | 2024 | 123072 | 0.310 |
Why?
|
| Consensus | 2 | 2022 | 606 | 0.310 |
Why?
|
| History, 20th Century | 2 | 2020 | 381 | 0.290 |
Why?
|
| Insurance, Health | 1 | 2017 | 138 | 0.270 |
Why?
|
| Aged | 15 | 2024 | 19094 | 0.270 |
Why?
|
| Insurance Coverage | 1 | 2017 | 121 | 0.270 |
Why?
|
| Middle Aged | 15 | 2024 | 25992 | 0.240 |
Why?
|
| Medicare | 1 | 2018 | 424 | 0.240 |
Why?
|
| Focus Groups | 2 | 2020 | 199 | 0.200 |
Why?
|
| Mortality | 2 | 2021 | 228 | 0.200 |
Why?
|
| Male | 19 | 2024 | 60081 | 0.200 |
Why?
|
| Nephritis, Interstitial | 1 | 2022 | 37 | 0.200 |
Why?
|
| Survival Rate | 3 | 2021 | 1997 | 0.190 |
Why?
|
| Kidney Glomerulus | 1 | 2021 | 80 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 35 | 0.190 |
Why?
|
| Female | 19 | 2024 | 65528 | 0.190 |
Why?
|
| Acid-Base Equilibrium | 1 | 2021 | 59 | 0.180 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 16 | 0.180 |
Why?
|
| China | 1 | 2021 | 240 | 0.180 |
Why?
|
| Language | 1 | 2021 | 202 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2021 | 4703 | 0.170 |
Why?
|
| Health Personnel | 1 | 2024 | 494 | 0.170 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 93 | 0.170 |
Why?
|
| Patients | 1 | 2020 | 121 | 0.160 |
Why?
|
| Disease Progression | 3 | 2020 | 2023 | 0.160 |
Why?
|
| Fatigue | 1 | 2020 | 216 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 164 | 0.160 |
Why?
|
| Hypertension | 1 | 2017 | 1286 | 0.160 |
Why?
|
| History, 19th Century | 1 | 2019 | 116 | 0.160 |
Why?
|
| Quality of Life | 3 | 2021 | 1928 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2020 | 269 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2020 | 229 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2020 | 162 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 161 | 0.150 |
Why?
|
| Hospitalization | 3 | 2021 | 1728 | 0.150 |
Why?
|
| Bacteriuria | 1 | 2019 | 82 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 354 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2021 | 458 | 0.140 |
Why?
|
| Pain | 1 | 2020 | 470 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 489 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2020 | 341 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 4513 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 1093 | 0.130 |
Why?
|
| Comorbidity | 3 | 2021 | 1496 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 1161 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.120 |
Why?
|
| Critical Care | 1 | 2020 | 648 | 0.120 |
Why?
|
| Registries | 1 | 2021 | 1395 | 0.120 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 621 | 0.110 |
Why?
|
| Adult | 10 | 2024 | 29010 | 0.110 |
Why?
|
| Biomarkers | 2 | 2021 | 2944 | 0.110 |
Why?
|
| Blood Pressure | 2 | 2020 | 1325 | 0.110 |
Why?
|
| Research Design | 2 | 2021 | 678 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 186 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 105 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1084 | 0.080 |
Why?
|
| Policy Making | 1 | 2018 | 59 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1862 | 0.070 |
Why?
|
| Clinical Studies as Topic | 1 | 2017 | 10 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2021 | 1473 | 0.070 |
Why?
|
| Program Development | 1 | 2018 | 189 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 8836 | 0.070 |
Why?
|
| Risk Factors | 4 | 2020 | 10016 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2018 | 450 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6371 | 0.060 |
Why?
|
| Medicaid | 1 | 2017 | 245 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2018 | 365 | 0.060 |
Why?
|
| Paraquat | 1 | 2022 | 13 | 0.050 |
Why?
|
| Agrochemicals | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cations | 1 | 2022 | 39 | 0.050 |
Why?
|
| Adolescent | 4 | 2021 | 19096 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12123 | 0.050 |
Why?
|
| Visual Analog Scale | 1 | 2020 | 7 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2021 | 47 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2021 | 40 | 0.050 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 38 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 30 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2021 | 169 | 0.040 |
Why?
|
| Frustration | 1 | 2020 | 9 | 0.040 |
Why?
|
| Nephrologists | 1 | 2020 | 13 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2020 | 24 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 24 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 126 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 139 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 226 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 190 | 0.040 |
Why?
|
| Comprehension | 1 | 2020 | 77 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 241 | 0.040 |
Why?
|
| Fear | 1 | 2020 | 201 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 96 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 317 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 404 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1305 | 0.040 |
Why?
|
| Psychometrics | 1 | 2020 | 657 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1308 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 16039 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 513 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1798 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 651 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3666 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2803 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2826 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3371 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 4352 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 3044 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2848 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5048 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 17538 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 33791 | 0.010 |
Why?
|